SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs earnings beat was overshadowed by softer revenue guidance, a reduced advertising outlook, and concerns about slowing growth, prompting analyst downgrades and price-target cuts. Traders are split between viewing the outlook and competition concerns as signs of a deeper growth problem and treating the selloff as an overreaction and buying opportunity.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro sharply raised its preliminary fiscal Q1 outlook on stronger AI-platform demand and improved gross-margin expectations, driving a rally. Traders largely welcomed the demand signal and speculated about a short squeeze, while skeptics questioned whether margins, cash flow and execution can sustain the move.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs strong third-quarter results, including its first profit as a public company and rapid AI-compute growth, prompted a rally and a wave of analyst upgrades. Traders are broadly upbeat, while skeptics point to heavy capital spending and upcoming share unlocks; a possible Tesla merger is also being discussed but remains exploratory.

AT&T, Inc. is a holding company, which engages in the provision of telecommunications and technology services. It operates through the Communications and Latin America segments. The Communications segment offers wireless, wireline telecom, and broadband services to businesses and consumers located in the US and businesses globally. The Latin America segment provides wireless services and equipment in Mexico. The company was founded in 1983 and is headquartered in Dallas, TX.

AT&T, Inc.

AT&T Inc

AT&Ts earnings beat and higher outlook failed to prevent a selloff, with traders pointing to postpaid phone additions falling short of expectations. The reaction is debated as either concern about subscriber momentum and lingering SpaceX competition or an overreaction to otherwise solid results, with some investors buying the dip.

Strive, Inc. engages in the provision of an asset management Bitcoin treasury. It is focused on maximizing value for shareholders, accumulating bitcoin and outperforming bitcoin over the long run. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani, and Kyle Fairbanks on March 9, 2022 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Strive Inc.

Strives preferred-stock offering and continued Bitcoin purchases are driving discussion, with bulls viewing the financing as fuel for treasury growth while skeptics warn that dilution and preferred-dividend obligations could weigh on common shareholders.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabets upcoming earnings have traders focused on Google Cloud growth and whether AI investments can generate returns, amid widespread concern about heavy capital spending and speculation it could rise further. The debate is split between dip-buyers citing Alphabets AI and cloud businesses and bearish traders worried about spending, search disruption, and the shares persistent weakness.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is drawing attention after a steep memory-stock selloff amid fears that Chinese rival CXMT could intensify competition and pressure memory prices, alongside broader weakness in chip stocks. Traders are split between viewing the shares as oversold ahead of earnings and expecting further declines as sector and competitive risks persist.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet is drawing attention for its sharp pullback and weak price action ahead of earnings, with traders watching whether cloud growth and AI investment can translate into returns. The discussion is split between dip-buyers citing its AI and quantum-computing progress and bearish traders focused on underperformance, technical support, and heavy capital spending.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BCRX is drawing attention amid persistent share-price weakness despite community references to ORLADEYO growth and profitable results, fueling criticism of management and calls for buybacks or a sale. Some traders point to future navenibart and Netherton data and continued ORLADEYO growth as potential catalysts, while skeptics focus on dilution, debt and uncertainty around the companys acquisition-led strategy.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Early Phase 1 azer-cel findings in progressive MS are the main focus, with traders highlighting reported deep B-cell depletion and disability or MRI signals as a potential growth story beyond BRIUMVI. The reaction is broadly optimistic but tempered by the small, preliminary study and uncertainty about whether the data will translate into meaningful clinical benefit; some also note the stocks muted, choppy response.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ADIL Stock Eyes Best Day In Over 5 Years — Major Pipeline Overhaul And $64M Raise Fuel Rally

Equity

Adial on Thursday announced that it has bought privately held Azora Therapeutics.

Adial Pharmaceuticals Applies For FDA Priority Voucher Program For AD04

(RTTNews) - Adial Pharmaceuticals, Inc. (ADIL) on Monday said it has submitted its AD04 application for consideration under the U.S. Food and Drug Administration Commissioner's National Priority Voucher Pilot Program (CNPV...

Adial Pharmaceuticals Lead Drug Fits New Policy Mood As Bipartisan Bill Signals Broader Lens On Alcohol Use Disorder

Adial backs H.R. 7091 targeting AUD in veterans, spotlighting harm reduction therapies and expanding research beyond abstinence-based care.read more...

Why Did Adial Pharmaceuticals Stock Plunge Over 20% After Hours Today?

The reverse split is intended to bring the company back into compliance with Nasdaq’s $1 minimum bid price rule.

Has Acurx Pharmaceuticals (ACXP) Outpaced Other Medical Stocks This Year?

Here is how Acurx Pharmaceuticals, Inc. (ACXP) and Adial Pharmaceuticals, Inc. (ADIL) have performed compared to their sector so far this year.

All You Need to Know About Adial Pharmaceuticals (ADIL) Rating Upgrade to Buy

Adial Pharmaceuticals (ADIL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Adial Pharmaceuticals (ADIL) Upgraded to Strong Buy: Here's Why

Adial Pharmaceuticals (ADIL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Retail Traders Flock To Adial Pharma After Patent News Sends Shares Soaring

Adial Pharmaceuticals jumped to its highest level since February after receiving a U.S. patent for its precision medicine approach to treating addiction. The patent supports the use of AD04 in patients with specific genetic markers.

Adial Pharmaceuticals Inc

Registration filing

Adial Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment or prevention of addiction and related disorders. It offers the AD04, a selective serotonin-3 antagonist. The company was founded by Bankole A. Johnson and William B. Stilley, III in November 2010 and is headquartered in Glen Allen, VA.

Bullish Sentiment

<ul class="summary-bullets"><li>The main goal of the deal is to bring Azora’s lead drug candidate, called AT177, into Adial’s pipeline.</li><li>Adial expects to begin the first human clinical trial for the experimental drug in mid-2027.</li><li>The firm is also raising up to $64 million in total through private financing as part of the deal.</li></ul>Shares of Adial Pharmaceuticals, Inc. (ADIL) jumped as much as 110% after the company announced the acquisition of privately held Azora Therapeutics, Inc., a biopharmaceutical company developing treatments for inflammatory diseases, in a transaction accompanied by up to $64 million in gross proceeds from a concurrent private placement financing.The stock is now on track for its best day since September 2020, if gains hold.The main goal of the deal is to bring Azora’s lead drug candidate, called AT177, into Adial’s pipeline. AT177 is an experimental once-daily pill designed to treat ulcerative colitis by working directly in the colon to reduce inflammation, while limiting effects on the rest of the body.The drug is currently in the final stages of lab and animal testing needed before it can be tested in humans. Adial expects to begin the first human clinical trial in mid-2027.The transaction marks a shift for Adial, which focuses on addiction treatments.<h2 class="st-heading-2">Terms Of The Deal</h2>Under the deal, Azora’s shareholders will receive Adial stock. After the transaction closes, former Azora shareholders will own about 51% of the combined company, current Adial shareholders about 8%, and new investors putting money into the financing about 41%. The deal has already been approved by both companies’ boards and by Azora’s shareholders. Adial will still need approval from its own shareholders for certain parts of the deal, which it plans to seek soon.Adial is also raising up to $64 million in total through private financing as part of the deal. Approximately $32 million will be invested immediately, while the remaining $32 million will be released once the company successfully begins its first human clinical trial of AT177. Proceeds will be used primarily to fund development of AT177 and initiate early-stage clinical studies, the company said.<h2 class="st-heading-2">How Did ADIL Retail Traders React?</h2>On Stocktwits, retail sentiment around ADIL stock jumped from ‘neutral’ to ‘bearish’ over the past 24 hours, while message volume stayed at ‘normal’ levels.A Stocktwits user termed the news “perfect” and expressed optimism for the stock rallying on Friday as well.<stembedurl>https://www.stocktwits.com/AtillaB/message/656149262</stembedurl>Another, however, expressed doubts about the deal.<stembedurl>https://www.stocktwits.com/fastmoneytraders/message/656149353</stembedurl>According to data from Koyfin, both analysts covering ADIL rate it ‘Buy’ or higher. The stock has a 12-month average price target of $25, which represents a potential upside of over 1000% from the stock’s last close.<a href="https://stocktwits.com/symbol/ADIL">ADIL stock</a> has fallen 39% over the year.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/ttd-stock-in-spotlight-after-firm-ropes-in-zendesk-marketing-chief-retail-hopes-new-hires-turn-things-around-at-trade-desk/cZKTDdaR728">TTD Stock In Spotlight After Firm Ropes In Zendesk Marketing Chief – Retail Hopes New Hires Turn Things Around At Trade Desk</a>For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

In this photo illustration, the Adial Pharmaceuticals logo is displayed on the screen of the tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Vanguard Extended Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$3.75
Prev Close	$3.82
Open	$3.75
Dividend Yield	0.00%
50-Day Moving Average	$4.80
Beta	0.76
Avg. Volume	47,372.56
PE Ratio	-0.23

52-Week High	$9.75
52-Week Low	$1.31
Market Capitalization	$10.03M
EPS (Annual)	-$11.93
Price to Book	-0.26
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

ADIL Fundamentals